Nyrada Inc CEO & Managing Director James Bonnar talked with Kerry Stevenson from Proactive at the ASX Small and Mid-Cap Conference about the company’s upcoming Phase 2 clinical trial for its lead drug candidate, Zoltrip, and the broader growth outlook for the business. Bonnar explained that the company is preparing to initiate a Phase 2 study in Australia targeting patients who have suffered a severe heart attack known as STEMI. The trial will recruit 100 patients across seven sites, with the primary goal of assessing safety while also identifying early signs of efficacy. As Bonnar stated, “we’re hoping to show in this study that the drug is, first of all, safe… but also that the drug is efficacious.” The drug is being developed as an adjunct therapy to standard treatments such as angioplasty, addressing the problem of reperfusion injury — a condition that can worsen heart damage when blood flow is restored. Nyrada is targeting a significant global market, with around 4 million angioplasty procedures performed annually. Importantly, Bonnar highlighted that there are currently no approved treatments for reperfusion injury, positioning Zoltrip as a potential first-in-class therapy. The drug targets TRP ion channels, a novel biological pathway with limited competition in clinical development. Beyond cardiac applications, Nyrada has also demonstrated promising results in traumatic brain injury and ischemic stroke, suggesting broader potential across multiple indications. Bonnar emphasised that the company expects strong news flow in the year ahead as trials progress and additional studies expand the drug’s application. #proactiveinvestors #ASX #NYR #Nyrada #ASX #NYR #Biotech #ClinicalTrials #Phase2 #HeartAttack #DrugDevelopment #HealthcareInnovation #Investing #SmallCaps #BiotechStocks #MedicalResearch #Stroke #TBI